Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Joey Tilton who wrote (332)	9/18/1998 9:46:00 AM
From: Joseph J. Clark	Read Replies (1) \| Respond to of 410

Front page of the WSJ for Sept 18.... "How a Breakthrough Quickly Broke Down for Johnson & Johnson" It's stent device transformed cardiac care, then left a big opening for rivals... Some highlights: Annual market (US) for stents is suring past 1 billion; Guidant Corp shares more than 80% of it with yet another competitor, Arterial Vascular Engineering (Yahoo!!!; that's my yahoo!, not in the article). Boston Scientific just won regulatory approval to enter the market. A Morgan Stanley analyst, who pegged J&J's market share at 91% at the end on 1996, expects it to plummet to 8% by the end of this year (wow). Though J&J is credited with changing the very way coronary artery disease is treated, they "didn't sustain the technology. They left the door oen for other manufacturers to come on the market with better designs." Great article, recommended reading for AVEI shareholders. Happy I'm in and look forward to everyone's opinion and continued discussion of this company!